Last reviewed · How we verify
Viscosupplements
Viscosupplements is a Small molecule drug developed by University Hospital, Grenoble. It is currently in Phase 2 development.
Viscosupplements, such as hyaluronic acid (HA) and RegenoGel-SP, are administered intra-articularly to treat conditions like osteoarthritis, degenerative disc disease, and knee osteoarthritis. Rexlemestrocel-L, a different type of viscosupplement, is also being studied for its potential therapeutic effects, often in combination with HA.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Viscosupplements |
|---|---|
| Sponsor | University Hospital, Grenoble |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- New Treatment of Knee Osteoarthritis (NA)
- ArtiAid® Plus for Knee Osteoarthritis: A Post-market Study (NA)
- ArtiAid® for Knee Osteoarthritis: A Post-market Study (NA)
- Temporomandibular Joint Arthrocentesis With Infiltration of PRP + Ropivacaine Versus PRP (PHASE4)
- Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain (PHASE3)
- Innovative Tool to Analyse Synovial Fluid of Patients With Knee Ostearthritis After IA Injection of Synvisc-one® (NA)
- A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis (PHASE2, PHASE3)
- The Effect of Intra-Articular Injection of RegenoGel-OSP™ (Self-Plasma) and RegenoGel™ on Knee Pain in People Suffering From Osteoarthritis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Viscosupplements CI brief — competitive landscape report
- Viscosupplements updates RSS · CI watch RSS
- University Hospital, Grenoble portfolio CI
Frequently asked questions about Viscosupplements
What is Viscosupplements?
Who makes Viscosupplements?
What development phase is Viscosupplements in?
Related
- Manufacturer: University Hospital, Grenoble — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing